See also this year's filing and all EDGAR filings for this company.
PDF Report 0001479290_2023_Revance_Therapeutics_Inc.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.11741699429584347, 'aggregate_val': 491697000, 'exp_sum': 440030000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 223934000, 'ResearchAndDevelopmentExpense': 101286000, 'remainder_Expenses': 114810000}} |
Graph
Absolute values for 0001479290, Revance Therapeutics Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 374,727,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 104,179,000 |
| 2 | PropertyPlantAndEquipmentNet | 22,139,000 |
| 3 | remainder_Assets | 80,855,000 |
| 4 | LiabilitiesCurrent | 75,682,000 |
| 5 | LiabilitiesNoncurrent | 114,244,000 |
| 6 | remainder_Liabilities | 379,374,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 223,934,000 |
| 9 | ResearchAndDevelopmentExpense | 101,286,000 |
| 10 | remainder_Expenses | 166,477,000 |
| 11 | remainder_Revenues | 132,565,000 |
| 12 | remainder_NetIncome | 2,710,000 |
| 13 | remainder_ComprehensiveNetIncome | -356,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 581,900,000 |
| 1 | Liabilities | 569,300,000 |
| 2 | Expenses | 491,697,000 |
| 3 | Revenues | 132,565,000 |
| 4 | StockholdersEquity | 12,600,000 |
| 5 | NetIncome | -356,422,000 |
| 6 | ComprehensiveNetIncome | -356,600,000 |
| 7 | BaseVar | 889,264,000 |
| 8 | EconomicCapitalRatio | -0.582 |
Edgar->Model Mapping
Feature Distribution
Change over Time
